Sign In
Buy QURE
$49.04
+4.65 (+10.48%)
At Close: Jun 23, 2026
uniQure Announces Pricing of Upsized $225 Million Public Offering
09:13pm, Tuesday, 23'rd Jun 2026
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
uniQure Announces $150 Million Proposed Public Offering
04:01pm, Monday, 22'nd Jun 2026
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
11:31am, Monday, 22'nd Jun 2026
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
03:20pm, Friday, 19'th Jun 2026
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~
UniQure: AMT-130's FDA Path Reaffirms My Bull Case
10:06am, Thursday, 18'th Jun 2026
QURE is now a more credible Huntington's disease gene-therapy story after the FDA reopened a near-term BLA path for AMT-130. The main bet is that AMT-130 could eventually become the first approved dis
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
08:31am, Thursday, 18'th Jun 2026
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring
03:40pm, Wednesday, 17'th Jun 2026
uniQure N.V. surges as the FDA now accepts Phase 1/2 data for AMT-130 as the primary basis for accelerated approval in Huntington's disease. QURE plans to submit its BLA for AMT-130 in Q3 2026, with a
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
02:12pm, Wednesday, 17'th Jun 2026
Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
12:12pm, Wednesday, 17'th Jun 2026
UniQure said it plans to seek approval for its experimental gene therapy for Huntington's disease. The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over
What made uniQure stock nearly double on Wednesday?
11:32am, Wednesday, 17'th Jun 2026
uniQure (QURE) stock is ripping higher this morning after the biopharmaceutical firm announced a major regulatory breakthrough with the FDA for its Huntington's disease gene therapy AMT-130. As invest
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
10:31am, Wednesday, 17'th Jun 2026
uniQure N.V. (NASDAQ:QURE) stock is up during Wednesday's premarket session as the company announced plans for a Biologics License Application (BLA) submission for AMT-130, a gene therapy treatment fo
This Biotech Stock Is Surging 66% on Surprise Good News From FDA
10:10am, Wednesday, 17'th Jun 2026
Gene therapy maker uniQure is one step closer to marketing its treatment for Huntington's disease.
UniQure gets FDA green light to file for Huntington's gene therapy approval
07:13am, Wednesday, 17'th Jun 2026
Dutch drugmaker UniQure said on Wednesday the U.S. Food and Drug Administration has agreed that data from a mid-stage study could support an accelerated approval filin
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease
07:05am, Wednesday, 17'th Jun 2026
~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~
